医師紹介

沖田 典子 | 浅井 克則 | 松橋 崇寛

沖田 典子

脳腫瘍の患者さんが当たり前の毎日が送れるよう、最善の治療を目指します。

略歴

2002年 大阪大学医学部卒業、大阪大学医学部附属病院研修医
2003年 堺市立総合医療センター 脳神経外科研修医
2004年 JCHO大阪病院(旧大阪厚生年金病院) 脳神経外科医員
2006年 大阪府立中河内救命救急センター医員
2010年 国立がん研究センター中央病院 脳脊髄腫瘍科チーフレジデント
2012年 大阪府立成人病センター 脳神経外科診療主任
2013年 大阪医療センター 脳神経外科医員
2018年 大阪国際がんセンター 脳神経外科副部長(院内部長)

資格

  • 医師免許
  • 日本脳神経外科学会認定専門医
  • 日本がん治療医認定機構がん治療認定医

受賞

  • 第2回国立がん研究センター医学会賞銅賞

所属学会

  • 日本脳神経外科学会
  • 日本脳神経外科コングレス
  • 日本脳腫瘍学会
  • 日本脳腫瘍の外科学会
  • 日本脳卒中学会
  • 日本脳腫瘍病理学会
  • 日本がん学会

業績

1. Arita H, Kinoshita M, Kawaguchi A, Takahashi M, Narita Y, Terakawa Y, Tsuyuguchi N, Okita Y, Nonaka M, Moriuchi S, Takagaki M, Fujimoto Y, Fukai J, Izumoto S, Ishibashi K, Nakajima Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Mori K, Ichimura K, Kanemura Y. Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Sci Rep. 2018 Aug 6;8(1):11773.
2. Sasaki T, Fukai J, Kodama Y, Hirose T, Okita Y, Moriuchi S, Nonaka M, Tsuyuguchi N, Terakawa Y, Uda T, Tomogane Y, Kinoshita M, Nishida N, Izumoto S, Nakajima Y, Arita H, Ishibashi K, Shofuda T, Kanematsu D, Yoshioka E, Mano M, Fujita K, Uematsu Y, Nakao N, Mori K, Kanemura Y. Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. J Neurooncol. 2018 Aug 3.
3. Okita Y, Narita Y. Phase III Studies on Adult Glioblastoma. No Shinkei Geka. 2018 Jul;46(7):561-571.
4. Okita Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Kinoshita M, Nonaka M, Nakajima S, Fujinaka T, Kanemura Y. Stereotactic image-based histological analysis reveals a correlation between 11C-methionine uptake and MGMT promoter methylation in non-enhancing gliomas. Oncol Lett. 2018, Aug;16(2):1924-1930.
5. Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, Watanabe Y, Shimosegawa E, Hatazawa J, Hashimoto N, Fujimoto Y, Kishima H. Influence of region-of-interest designs on quantitative measurement of multimodal imaging of MR non-enhancing gliomas.Oncol Lett. 2018 May;15(5):7934-7940.
6. Hayashi N, Takahashi H, Hasegawa Y, Higuchi F, Takahashi M, Makino K, Takagaki M, Akimoto J, Okuda T, Okita Y, Mitsuya K, Hirashima Y, Narita Y, Nakasu Y; Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical Society. A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer. BMC Cancer. 2017 Jun 2;17(1):397.
7. Okita Y, Masuda N, Mizutani M, Kodama Y, Mori K, Mano M, Nakagawa T, Nakajima S, Fujinaka T. Widespread subdural metastasis from breast cancer progressing rapidly with cerebral herniation: A case report. Mol Clin Oncol. 2017 Jun;6(6):960-962.
8. Kanemura Y, Sumida M, Okita Y, Yoshioka E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Inazawa Y, Takada AI, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M. Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. Anticancer Res. 2017 Jul;37(7):3921-3932.
9. Kinoshita M, Arita H, Okita Y, Kagawa N, Kishima H, Hashimoto N, Tanaka H, Watanabe Y, Shimosegawa E, Hatazawa J, Fujimoto Y, Yoshimine T. Comparison of diffusion tensor imaging and 11C-methionine positron emission tomography for reliable prediction of tumor cell density in gliomas. J Neurosurg. 2016 Nov;125(5):1136-1142.
10. Okita Y, Narita Y, Miyakita Y, Miyahara R, Ohno M, Takahashi M, Nonaka M, Kanemura Y, Nakajima S, Fujinaka T. Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. Mol Clin Oncol. 2016 Sep;5(3):179-185.
11. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K*. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016 Aug 8;4(1):79.
12. Umehara T, Okita Y, Nonaka M, Kanemura Y, Kodama Y, Mano M, Nakajima S, Fujinaka T. A case of pilocytic astrocytoma requiring tumor resection during pregnancy. Molecular and Clinical Oncology. 2016 Apr;4(4):567-570.
13. Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, Fujimoto Y, Kishima H, Kanemura Y, Nonaka M, Nakajima S, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas. AJNR Am J Neuroradiol. 2016 Jan;37(1):44-50.
14. Okita Y, Narita Y, Miyahara R, Miyakita Y, Ohno M, Shibui S. Health-related quality of life in long-term survivors with Grade II gliomas: the contribution of disease recurrence and Karnofsky Performance Status. Jpn J Clin Oncol. 2015 Oct;45(10):906-13.
15. Umehara T, Okita Y, Nonaka M, Mori K, Kanemura Y, Kodama Y, Mano M, Kudawara I, Nakajima S. Choroid Plexus Metastasis of Follicular Thyroid Carcinoma Diagnosed due to Intraventricular Hemorrhage. Intern Med. 2015;54(10):1297-302.
16. Yamada S, Okita Y, Shofuda T, Yoshioka E, Nonaka M, Mori K, Nakajima S, Kanemura Y. Ipsilateral hemiparesis caused by putaminal hemorrhage in a patient with horizontal gaze palsy with progressive scoliosis: a case report. BMC Neurol. 2015 Mar 10;15:25.
17. Okita Y, Nonaka M, Umehara T, Kanemura Y, Kodama Y, Mano M, Nakajima S. Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report. Oncol Lett. 2015 Apr;9(4):1885-1888. Oncol Lett. 2015 Apr;9(4):1885-1888.
18. Okita Y, Nonaka M, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, Nakajima S, Kanemura Y. (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. Clin Neurol Neurosurg. 2014 Oct;125:212-6.
19. Okita Y, Narita Y, Suzuki T, Arita H, Yonemori K, Kinoshita T, Fujiwara Y, Tsuda H, Komoike Y, Nakagawa H, Tamaki Y, Tomita Y, Shibui S, Maruno M. Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol. 2013 Nov;1(6):995-1001.
20. Kinoshita M, Sasayama T, Narita Y, Yamashita F, Kawaguchi A, Chiba Y, Kagawa N, Tanaka K, Kohmura E, Arita H, Okita Y, Ohno M, Miyakita Y, Shibui S, Hashimoto N, Yoshimine T.Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis. Neuro Oncol. 2014 May;16(5):728-34.
21. Arita H, Narita Y, Ohno M, Miyakita Y, Okita Y, Ide T, Shibui S. Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report. Childs Nerv Syst. 2013 Feb;29(2):341-5.
22. Okita Y, Narita Y, Miyakita Y, Ohno M, Nagai S, Shibui S. Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids. Intern Med. 2012;51(20):2967-71.
23. Kinoshita M, Arita H, Goto T, Okita Y, Isohashi K, Watabe T, Kagawa N, Fujimoto Y, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. A novel PET index, 18F-FDG-11C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med. 2012 Nov;53(11):1701-8.
24. Okita Y, Narita Y, Yoshida A, Miyakita Y, Ohno M, Saio M, Yoshimi N, Shibui S. The late recurrence of ganglioneuroma 21 years after initial presentation with neuroblastoma. Pediatr Hematol Oncol. 2012 Oct;29(7):647-51.
25. Ohno M, Narita Y, Miyakita Y, Okita Y, Kayama T, Shibui S. Development of secondary skull sarcoma after treatment for childhood acute myeloid leukemia. Asia Pac J Clin Oncol. 2012 Dec;8(4):e49-52.
26. Okita Y, Narita Y, Miyakita Y, Ohno M, Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T, Shibui S. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol. 2012 Oct;41(4):1325-36.
27. Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. Brain Tumor Pathol. 2012 Oct;29(4):183-91.
28. Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Maeshima A, Kayama T, Shibui S. Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed? Clin Neurol Neurosurg. 2012 Nov;114(9):1217-21.
29. Fukushima S, Narita Y, Shinomiya A, Ohno M, Miyakita Y, Okita Y, Hanakawa K, Ide T, Kayama T, Shibui S, Tsuda H. A case of unclassified high-grade glioma with polar spongioblastoma pattern. Neuropathology. 2012 Dec;32(6):604-10.
30. Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Kayama T, Shibui S. Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 2012 Oct;29(4):192-200.
31. Chiba Y, Kinoshita M, Okita Y, Tsuboi A, Isohashi K, Kagawa N, Fujimoto Y, Oji Y, Oka Y, Shimosegawa E, Morita S, Hatazawa J, Sugiyama H, Hashimoto N, Yoshimine T. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. J Neurosurg. 2012 Apr;116(4):835-42.
32. Hashimoto N, Rabo CS, Okita Y, Kinoshita M, Kagawa N, Fujimoto Y, Morii E, Kishima H, Maruno M, Kato A, Yoshimine T. Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg. 2012 Mar;116(3):574-80.
33. Arita H, Kinoshita M, Okita Y, Hirayama R, Watabe T, Ishohashi K, Kijima N, Kagawa N, Fujimoto Y, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography. J Neurooncol. 2012 Apr;107(2):379-86.
34. Kinoshita M, Goto T, Arita H, Okita Y, Isohashi K, Kagawa N, Fujimoto Y, Kishima H, Shimosegawa E, Saitoh Y, Hatazawa J, Hashimoto N, Yoshimine T. Imaging ¹⁸F-fluorodeoxy glucose/¹¹C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema. J Neurooncol. 2012 Jan;106(2):417-25.
35. Okita Y, Narita Y, Miyakita Y, Ohno M, Aihara K, Mori S, Kayama T, Shibui S. Reactivation of cytomegalovirus following treatment of malignant glioma with temozolomide. Int Canc Conf J (2012) 1:53–57
36. Arita H, Izumoto S, Kinoshita M, Okita Y, Hashimoto N, Fujita T, Ichimaru N, Takahara S, Yoshimine T. Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports. Neurol Med Chir (Tokyo). 2010;50(12):1079-83.
37. Yamamoto F, Hashimoto N, Kagawa N, Okita Y, Chiba Y, Kijima N, Kinoshita M, Yoshizu K, Fujimoto Y, Hirai K, Yoshimine T. A survey of disclosure of diagnosis to patients with glioma in Japan. Int J Clin Oncol. 2011 Jun;16(3):230-7.
38. Kinoshita M, Yoshioka Y, Okita Y, Hashimoto N, Yoshimine T. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody. Contrast Media Mol Imaging. 2010 Jan-Feb;5(1):18-22.
39. Kinoshita M, Hashimoto N, Izumoto S, Okita Y, Kagawa N, Maruno M, Ohnishi T, Arita N, Yoshimine T. Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy. Kinoshita M, Hashimoto N, Izumoto S, Okita Y, Kagawa N, Maruno M, Ohnishi T, Arita N, Yoshimine T. J Neurooncol. 2010 Aug;99(1):95-101.
40. Okita Y, Kinoshita M, Goto T, Kagawa N, Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. (11)C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: A stereotactic image-histology comparison. Neuroimage. 2010 Feb 15;49(4):2977-82.
41. Goto Y, Hashimoto N, Okita Y, Goto T, Rabo C, Hirayama H, Horikawa Y, Kinoshita M, Kagawa N, Yoshimine T. A surgically treated case of Lhermitte-Duclos disease with a precise natural history and high uptake of FDG on PET. J Neurooncol. 2010 May;97(3):445-50.
42. Kinoshita M, Goto T, Okita Y, Kagawa N, Kishima H, Hashimoto N, Yoshimine T. Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema. J Neurooncol. 2010 Feb;96(3):409-15.
43. Kinoshita M, Hashimoto N, Goto T, Yanagisawa T, Okita Y, Kagawa N, Kishima H, Tanaka H, Fujita N, Shimosegawa E, Hatazawa J, Yoshimine T. Use of fractional anisotropy for determination of the cut-off value in 11C-methionine positron emission tomography for glioma. Neuroimage. 2009 Apr 1;45(2):312-8.

ページトップへ